# A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

> **NCT07030712** · PHASE1 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 67 (estimated)

## Conditions studied

- Metastatic Neoplasm

## Interventions

- **DRUG:** MK-8294
- **DRUG:** MK-8294
- **DRUG:** MK-8294
- **DRUG:** MK-8294
- **DRUG:** MK-8294
- **DRUG:** MK-8294
- **DRUG:** MK-8294
- **DRUG:** MK-8294
- **OTHER:** CD8 PET Tracer

## Key facts

- **NCT ID:** NCT07030712
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-23
- **Primary completion:** 2027-08-23
- **Final completion:** 2027-08-23
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07030712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07030712, "A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07030712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*